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Background: For patients who experience dry eye after phacoemulsification, vision and quality of life can
significantly deteriorate. In this study, the efficacy and safety of carboxymethylcellulose sodium (CMC) 1%
ophthalmic solution combined with conventional therapy in treating dry eye signs and symptoms after
phacoemulsification were evaluated.
Methods: In this prospective, multicenter, open-label, controlled study, 180 patients with age-related cataract were
randomized to treatment with conventional therapy plus CMC 1% (n = 90) or to conventional therapy only (control
group, n = 90) after phacoemulsification and intraocular lens implantation. Tear breakup time (TBUT), the Schirmer
test with anesthesia, and fluorescein and lissamine green staining were performed. The Ocular Surface Disease Index
(OSDI) questionnaire and a patient subjective symptom evaluation were administered preoperatively (baseline) and
postoperatively at 7 and 30 days.
Results: TBUT was significantly longer in the treatment group compared with the control group at day 7 (8.5 ± 5.5 versus
6.6 ± 3.8 s; P = 0.0475) and day 30 (9.0 ± 5.9 versus 6.7 ± 4.8 s; P = 0.0258) after surgery. Compared with baseline, TBUT
significantly increased in patients in the treatment group (P < 0.001 at both day 7 and day 30) with a presurgical diagnosis
of dry eye, but significantly decreased in patients in the control group (P < 0.02 at both day 7 and day 30) with no prior
diagnosis of dry eye. Fluorescein and lissamine staining, OSDI questionnaire and subjective symptom scores all
improved from baseline, with no significant differences between the two groups. No significant differences in
tolerability and safety were observed between the group receiving CMC and conventional therapy, and those
receiving conventional therapy only.
Conclusion: Treatment with CMC 1% can provide significant improvement in tear film stability after
phacoemulsification for age-related cataract.
Trial registration: ClinicalTrials.gov identifier NCT02028754 (Date of registration: Jan. 6, 2014).
Keywords: Carboxymethylcellulose, Dry eye, Phacoemulsification, Cataract surgery* Correspondence: xlren@zju.edu.cn
1Eye Center, Second Affiliated Hospital, Zhejiang University School of
Medicine, Hangzhou, China
Full list of author information is available at the end of the article
© 2015 Yao et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yao et al. BMC Ophthalmology  (2015) 15:28 Page 2 of 10Background
Dry eye is a multifactorial disease of the tears and ocular
surface that results in symptoms of discomfort, visual
disturbance, and tear film instability, with potential dam-
age to the ocular surface [1,2]. Highly prevalent world-
wide, dry eye has several risk factors, including age,
contact lens wear, diet, smoking, history of allergy or
diabetes, and activities that involve prolonged and
demanding visual tasks (eg, use of computers, smart
phones, and other devices) [3]. Quality of life may be
significantly impacted with the conduct of daily activities
such as reading, driving, and work using computer
screens potentially affected [4].
With the advancement of medical technology, cataract
surgery (phacoemulsification with intraocular lens [IOL]
implantation) has become a routine procedure; however,
for patients who experience dry eye after phacoemulsifi-
cation, vision and quality of life can significantly deteri-
orate. Clinical evaluation of dry eye after cataract
surgery has demonstrated worsening of patient subjec-
tive symptom scores, reductions in tear film breakup
time (TBUT) and goblet cell density, as well as increased
corneal and conjunctival staining, indicating deteriorat-
ing disease [5-7]. Various factors may further impact the
health of the ocular surface following cataract surgery,
including age, the external environment, poor systemic
health, concurrent ocular surface disease, reflex secretory
block caused by nerve injury, and ocular epithelial injury
during the operation [1,8]. Increased ocular discomfort
reported after cataract surgery may be a result of failure to
diagnose dry eye before surgery and/or subsequent inad-
equate treatment after cataract surgery.
Conventional therapy following cataract surgery includes
topical corticosteroids or non-steroidal anti-inflammatory
drugs to manage inflammation, and anti-infectives. The
effectiveness of corticosteroids in managing dry eye after
cataract surgery has been evaluated [9,10]. However, few
studies have assessed the addition of artificial tears to con-
ventional therapy for treatment of dry eye after cataract sur-
gery [11]. The objective of this study was to investigate the
efficacy and safety of carboxymethylcellulose sodium
(CMC) 1% ophthalmic solution added to conventional ther-
apy in stabilizing tear film and treating preexisting dry eye
or dry eye resulting from phacoemulsification.
Methods
This prospective, open-label, interventional, randomized,
controlled study was conducted at eight clinical sites in
China between October 2011 and May 2013. The study
protocol was approved by the central ethics committee
(Ethics Committee of the Second Hospital of Zhejiang
Medical University) and two branch ethics committees
(Ethics Committee of Daping Hospital of The Third
Military Medical University and Ethics Committee ofEye, Ear, Nose and Throat Hospital of Fudan University).
The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki, and all patients
signed an informed consent form before enrollment.
Patients
Male or female patients aged 60 to 80 years with age-
related cataract were enrolled. Patients were scheduled
to undergo phacoemulsification and IOL implantation
and had a lens nucleus hardness of grade 3 or less (based
on nucleus color per the standard Lens Opacities Classi-
fication System III [12]). Excluded were patients with
allergy to any of the study medications, conjunctival
allergy or infectious disease, history of ocular chemical
or thermal burn, Stevens-Johnson syndrome or ocular
pemphigoid, glaucoma or ocular hypertension, eyelid or
lacrimal disease, any ocular operation within 3 months
prior to enrollment, corneal contact lens wear, history of
serious systemic disease, or other conditions that in
the opinion of the investigator precluded enrollment.
Patients were withdrawn from the study if they experi-
enced complications during surgery, or post-surgical
ocular hypertension, endophthalmitis, infectious keratitis,
or conjunctivitis.
Randomization and treatment administration
Patients who provided informed consent were enrolled
in the study by their treating physician, and were
assigned a sequential number with a corresponding
randomization code generated by an independent
third party using SAS software (version 8.0, SAS Insti-
tute Inc, Cary, NC). According to the randomization
code, clinical staff assigned patients to receive either
study treatment plus conventional post-surgical ther-
apy consisting of (1) prednisolone acetate ophthalmic
suspension 1% (Pred Forte®, Allergan, Inc., Irvine, CA)
instilled four times daily in the first post-surgical
week, three times daily in the second week, twice daily
in the third week, and once daily for the remainder of
the study, and (2) levofloxacin 0.5% ophthalmic solu-
tion (Cravit®, Santen Pharmaceutical Co, Ltd, Osaka,
Japan), or conventional therapy alone (control group)
instilled four times daily in the first post-surgical
week. The clinical staff provided treatment medica-
tions and instructions on how to administer ophthal-
mic solutions according to the assigned randomization
group.
Topical anesthesia with oxybuprocaine hydrochloride
0.4% eye drops (Benoxil, Santen Pharmaceutical Co, Ltd,
Osaka, Japan) or proparacaine hydrochloride 0.5% eye
drops (Alcaine®, Alcon Laboratories, Inc, Ft Worth, TX)
was administered before the surgical procedure. After
surgery, the study treatment group instilled CMC sodium
1% ophthalmic solution (Refresh Liquigel®, Allergan, Inc.,
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surgical therapy for the first 30 days. The control group
received conventional post-surgical therapy only. During
the study, use of other topical ophthalmologic agents with
a potential impact on efficacy assessment of the study
treatment was prohibited.Clinical assessments
Patients were evaluated 3 to 5 days before phacoemulsi-
fication and IOL implant surgery (baseline), as well as 7
and 30 days post-surgery to assess the benefit of CMC
1% at early and later time points. On the day of each of
the three visits, administration of CMC was withheld
prior to and immediately after study assessments. The
following were conducted in sequence: TBUT, fluores-
cein and lissamine green ocular staining, and Schirmer
test with oxybuprocaine hydrochloride 0.4% eye drops
(Benoxil, Santen Pharmaceutical Co, Ltd) or propara-
caine hydrochloride 0.5% eye drops (Alcaine®, Alcon
Laboratories, Inc) as anesthetics (and test strips from
Tianjin Jingming New Technological Development Co,
Ltd, Tianjin, China). The Ocular Surface Disease Index
(OSDI) questionnaire and patient subjective symptom
evaluation were also completed at each visit, prior to the
above tests.
The primary efficacy outcome, TBUT, was measured
in seconds after placing a fluorescein sodium test strip
on the lower eye lid. Fluorescein staining was conducted
to assess corneal epithelial damage and was graded on a
4-point scale in three corneal regions: upper, middle,
and lower. Corneal and conjunctival staining were also
performed by placing a lissamine green test strip (Intra
Ocular Care Pvt. Ltd, Bangalore, India) on the lower eye
lid. Five regions, the temporal and nasal conjunctival
regions and three corneal regions (upper, middle, and
lower), were assessed. Corneal and conjunctival were
graded in each region as 0 = no staining; 1 = staining less
than half the area; 2 = staining an area greater than half
but not the whole region; and 3 = staining of the whole
region. The Schirmer test was performed to evaluate
basic secretion from the lacrimal glands [13].
The standard OSDI questionnaire and a patient sub-
jective symptom evaluation form were used to evaluate
dry eye symptoms. In the OSDI questionnaire, 12
questions assessed visual function, ocular symptoms,
and potential environmental triggers. The subjective
evaluation form included 11 symptoms: foreign body
sensation, photophobia, itching, pain in the eyes, dry
eyes, eye heaviness, blurred vision, eye fatigue, eye dis-
comfort, eye secretions, and tearing. Each symptom was
graded as 0 = no symptom; 1 = occasional symptoms;
2 = intermittent mild symptoms; and 3 = persistent clear
symptoms.The clinical investigator was responsible for monitor-
ing adverse events (eg, eye swelling, ocular hypertension)
and reporting incidents to the study sponsor. Any wors-
ening of pre-existing dry eye symptoms (eg, tearing, for-
eign body sensation, or photophobia) or new occurrence
of such symptoms was also considered an adverse event.
Data analysis and statistical methods
Patients were diagnosed as having dry eye symptoms if
they met one of the following conditions: TBUT ≤5 s,
plus a subjective symptom score of 3 or greater [14,15],
or Schirmer test ≤3 mm in 5 min, plus a subjective
symptom score of 3 or greater [14,16]. The effectiveness
of treatment with 1% CMC in relieving dry eye symp-
toms was assessed by comparing differences in clinical
assessments between the treatment group and control
group. Pre- and post-surgery differences were also deter-
mined within the treatment and control groups. Sub-
group analyses were performed in patients with and
without a diagnosis of dry eye before surgery.
Quantitative data were compared between the two
groups using the t-test (normal distribution) and the
Wilcoxon rank sum test (non-normal distribution).
Similarly, differences before and after surgery within the
treatment and control groups were assessed using paired
t-tests (normal distribution) and Wilcoxon signed rank
test (non-normal distribution). P < 0.05 was considered
to be statistically significant. Statistical analysis was per-
formed using SAS (version 8.0).
Sample size for the study was based on results from an
early study, in which the value of TBUT was determined
to be 4.2 ± 2.7 s in the control group and 7.3 ± 4.9 s in
the artificial tear group at day 7 after cataract surgery
[17]. One-tailed test was conducted with α = 0.05 and
β = 0.2, and it was determined that at least 31 patients
per group were required to detect superiority between
the treatment groups. Taking patient discontinuation
into consideration, as well as post-surgery follow-up
visits at both day 7 and day 30, it was estimated that a
sample size of 90 patients in each group was required
for the intent-to-treat (ITT) population.
Results
A total of 180 patients were enrolled and formed the
ITT population—90 patients were randomized to each
study group. Among the enrolled patients, seven
patients in the treatment group and eight patients in the
control group did not complete the study (Figure 1).
Baseline characteristics were well balanced between the
two groups (Table 1). Overall, 52.3% and 47.7% of
patients in the treatment group had surgery in the right
and left eye, compared with 55.5% and 44.4% in the con-
trol group, respectively. The percentage of patients who
had a superior (12 o’clock), temporal (9 o’clock), tempo-
Figure 1 Patient disposition. ITT, intent to treat; CMC, carboxymethylcellulose sodium; SS, safety set.
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(10–11 or 11–12 o’clock) incision was also similar be-
tween both groups. The mean incision length (± SD)
was 2.8 ± 0.3 cm versus 2.8 ± 0.4 cm in the treatment
and control groups, respectively.
Dry eye diagnosis before and after surgery
Based on the criteria for diagnosis of dry eye in this
study, the percentage of patients considered to have dry
eye disease before surgery was similar in both the treat-
ment and control groups. At day 7 after surgery, the
number of patients with dry eye decreased to 22 (24.4%)
in the treatment group but increased slightly to 35
(38.9%) in the control group (P = 0.0373 between
groups) (Figure 2). By day 30 following cataract surgery,Table 1 Baseline demographics and disease characteristics
Baseline characteristic Treatment g
Age, years (mean ± SD) 68.8 ± 7.1
Female, n (%) 54 (60.0)
Patient with concomitant systemic diseases, n (%) 25 (27.8)
TBUT, s (mean ± SD) 7.7 ± 4.8
Schirmer test, mm (mean ± SD) 12.6 ± 6.9
Percentage of patients with dry eye, n (%)
TBUT ≤5 s + symptom score ≥3 34 (37.8)
Schirmer test ≤3 mm+ symptom score ≥3 2 (2.2)
Total patients with dry eye 35 (38.9)
SD, standard deviation; TBUT, tear film breakup time.
*Wilcoxon rank sum test.
**Chi-square test.25 (27.8%) patients in the treatment group and 31
(34.4%) in the control group had dry eye (P = 0.3340
between groups).
Among the group of patients with dry eye before
surgery, a significantly lower number of patients con-
tinued to have dry eye after surgery in the treatment
group (16; 45.7%) compared with the control group
(25; 75.8%) at day 7 (P = 0.0114). At day 30, no signifi-
cant differences were found in the number of patients
with post-surgical dry eye in the two groups (17
[48.6%] versus 20 [60.6%]). In the subgroup of patients
without dry eye before surgery, no differences were
observed between the two groups at both day 7 (6 [10.9%]
versus 10 [17.5%]) and day 30 (8 [14.5%] versus 11 [19.3%])
post-surgery.roup (n = 90) Control group (n = 90) P value
69.0 ± 7.1 0.9349*
59 (65.6) 0.4407**
26 (28.9) 0.8686**
7.2 ± 4.1 0.7583*




Figure 2 Percentage of patients with dry eye according to
study criteria, at baseline and at days 7 and 30 after cataract
surgery. *P = 0.0373 compared with control group.
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After cataract surgery, TBUT (mean ± SD) was signifi-
cantly greater in the treatment group than the control
group at both day 7 and day 30 (Figure 3A; Table 2).
Compared with baseline, TBUT increased at days 7 and
30 in the treatment group, but decreased at both time
points in the control group (Table 2).
Subgroup analysis in patients diagnosed with dry eye
prior to cataract surgery demonstrated no statistically
significant differences in TBUT between the treatment
group and control group at days 7 and 30 (Figure 3B;
Table 2). However, there was a statistically significant
increase from baseline in TBUT in the treatment group
(P < 0.001). In contrast, no improvements in TBUT were
observed in the control group up to 30 days after sur-
gery (Table 2). Among patients without dry eye prior to
cataract surgery, significant differences were observed in
TBUT between the treatment and control groups at days
7 and 30 (Figure 3C; Table 2). In the control group,
there was a statistically significant decrease from base-
line in TBUT at both time points. In the treatment
group, no significant changes were noted from baseline
at both day 7 and day 30 (Table 2).
Schirmer test
No significant differences were observed in the Schirmer
test (mean ± SD) between the two groups at both day 7
and day 30 after cataract surgery (Table 3). No signifi-
cant changes in Schirmer test scores were reported ineither group at day 7 or day 30 compared with baseline.
No differences were observed in subgroup analyses of
patients with dry eye or those without dry eye prior to
cataract surgery.
Fluorescein and lissamine green staining
No differences in fluorescein staining scores (mean ±
SD) were observed between the treatment and control
groups at either day 7 or day 30 post-surgery. However,
fluorescein scores significantly decreased from baseline
at day 30 in the treatment and control groups (Table 3).
No significant improvements compared with baseline
were observed among patients with dry eye before
cataract surgery. For patients without dry eye before
surgery, fluorescein staining score at day 30 post-surgery
decreased significantly from baseline in the treatment
group (2.1 ± 3.1 to 1.0 ± 1.8; P < 0.001); no significant
changes were observed in the control group.
Lissamine green staining scores (mean ± SD) were not
significantly different between the two groups at day 7
and day 30 post-surgery. Similar to fluorescein scores,
there were significant decreases from baseline in lissa-
mine green scores at day 30 in both the treatment and
control groups (Table 3). Among patients with dry eye
before surgery, no significant improvements were
observed in lissamine green staining at day 7 and day 30
post-surgery. For patients without dry eye prior to sur-
gery, lissamine green scores significantly decreased from
baseline at day 7 in the control group (2.8 ± 2.9 to 2.2 ±
2.4; P = 0.0233) and at day 30 in the treatment group
(3.1 ± 3.5 to 2.1 ± 2.4; P = 0.0009).
OSDI questionnaire and patient subjective symptom
evaluation
No differences were reported in OSDI and patient sub-
jective symptom scores (mean ± SD) between the treat-
ment group and control group at day 7 and day 30
following cataract surgery. However, both OSDI and
subjective symptom scores significantly decreased from
baseline at day 7 and day 30 post-cataract surgery in
both groups (Table 4). In subgroup analyses of patients
with and without dry eye before cataract surgery, no sig-
nificant differences in mean OSDI and subjective symp-
tom scores were observed between the treatment and
control groups at day 7 and day 30 post-surgery. Com-
pared with baseline, there were significant decreases in
OSDI and symptom scores within the treatment group
and control group at both days 7 and 30 post-surgery.
Reductions in the scores were not significantly different
between the groups, except for the mean subjective
symptom score at day 30 after cataract surgery in
patients without dry eye (12.1 ± 6.5 to 4.8 ± 3.5 in the
treatment group versus 11.0 ± 5.7 to 5.5 ± 4.0 in the
control group; P = 0.0466).
Figure 3 Tear film breakup time (TBUT) at baseline and at days
7 and 30 after surgery. (A) All patients undergoing cataract
surgery. (B) Subgroup of patients with dry eye before cataract
surgery. (C) Subgroup of patients without dry eye before cataract
surgery. *P≤ 0.0475; **P ≤ 0.0168 compared with control group;
error bars represent standard error mean.
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A total of 171 patients, 86 in the treatment group and
85 in the control group, formed the safety analysis set.
No significant differences were noted in safety between
the groups; 5 (5.8%) patients in the treatment group and
4 (4.7%) patients in the control group experienced
adverse events (Table 5). The most common adverse
events reported were high intraocular pressure in the
treatment group, and foreign body sensation in the con-
trol group (Table 5).
Discussion
Dry eye is a common condition following cataract sur-
gery and can be a significant cause of vision impairment,
reducing patients’ quality of life. In this study, 37.78% of
all patients were diagnosed with dry eye at baseline
based on the study criteria. The proportion was higher
than the 20% to 30% that has been reported for the gen-
eral population in China [18,19].
Aging is an established risk factor for dry eye [3], and
androgen deficiency associated with aging has also been
reported to be a contributing factor to dry eye [20,21].
The patient population enrolled in this study, aged 60 to
80 years with age-related cataract, was at greater risk of
dry eye disease. Patients with TBUT ≤5 s, plus a subjec-
tive symptom score of ≥3, constituted 36.67% of the total
patient population, and 97.06% of patients who enrolled
in the study had been diagnosed with dry eye before
phacoemulsification. This observation indicates that a
majority of patients with dry eye prior to cataract sur-
gery may have poor tear film stability and accompanying
symptoms.
This study demonstrated that by day 7 after phaco-
emulsification, the percentage of patients with dry eye
decreased from 38.9% to 24.4% in the treatment group,
but remained relatively stable (36.7%-38.9%) in the control
group. The findings indicate that cataract surgery may
worsen dry eye (as has been previously reported), and
further suggest that the addition of CMC 1% to conven-
tional post-surgical therapy may help prevent develop-
ment/worsening of dry eye after phacoemulsification.
Since neither patients nor investigators were masked to
treatment, patients in the control group were likely
aware of their treatment status, which could explain the
above findings. However, despite this potential limitation
of the study, the difference in the percentage of patients
with dry eye between the treatment and control groups
Table 2 TBUT at baseline and days 7 and 30 after cataract surgery
TBUT in patient subgroups
Treatment group Control group P
value*n Score n Score
All patients, seconds (mean ± SD)
Baseline 90 7.7 ± 4.8 90 7.2 ± 4.1 0.7583
At day 7 85 8.5 ± 5.5 85 6.6 ± 3.8 0.0475
At day 30 83 9.0 ± 5.9 82 6.7 ± 4.8 0.0258
Change from baseline at day 7 85 0.9 ± 4.9 85 −0.5 ± 3.4** 0.0171
Change from baseline at day 30 83 1.3 ± 5.6** 82 −0.4 ± 4.4** 0.0093
Dry eye prior to surgery subgroup, s (mean ± SD)
Baseline 35 3.5 ± 1.2 33 3.8 ± 1.0 0.2912
At day 7 33 5.4 ± 3.8 32 4.5 ± 2.4 0.5064
At day 30 32 5.7 ± 4.2 31 4.1 ± 2.0 0.3146
Change from baseline at day 7 33 2.0 ± 3.6*** 32 0.7 ± 2.2 0.0805
Change from baseline at day 30 32 2.3 ± 3.8*** 31 0.3 ± 2.0 0.0365
Non-dry eye prior to surgery subgroup, s (mean ± SD)
Baseline 55 10.3 ± 4.4 57 9.2 ± 4.0 0.1283
At day 7 52 10.5 ± 5.6 53 7.8 ± 4.0 0.0168
At day 30 51 11.0 ± 6.0 51 8.3 ± 5.4 0.0164
Change from baseline at day 7 52 0.1 ± 5.5 53 −1.3 ± 3.8** 0.1300
Change from baseline at day 30 51 0.7 ± 6.4 51 −0.9 ± 5.3** 0.1501
TBUT, tear breakup time; SD, standard deviation.
*P values for the difference between groups calculated using Wilcoxon rank sum test.
**P ≤ 0.0349; ***P ≤ 0.0007 for change from baseline calculated using Wilcoxon signed rank test.
Significant differences between treatment groups and significant changes from baseline are indicated in bold font.
Table 3 Schirmer test, fluorescein staining, and lissamine green staining at baseline and after cataract surgery
Clinical assessment
Treatment group Control group
P
value*n Score n Score
Schirmer test, mm (mean ± SD)
Baseline 90 12.6 ± 6.9 90 12.9 ± 6.9 0.6800
At day 7 85 11.8 ± 5.6 85 12.5 ± 6.8 0.6620
At day 30 83 12.7 ± 6.1 82 12.6 ± 6.5 0.6929
Change from baseline at day 7 85 −0.8 ± 5.9 85 −0.3 ± 5.1 0.9055
Change from baseline at day 30 83 0.0 ± 5.4 82 −0.1 ± 5.6 0.6889
Fluorescein staining score (mean ± SD)
Baseline 90 2.0 ± 2.8 90 1.7 ± 2.6 0.4084
At day 7 85 2.0 ± 2.8 85 1.8 ± 2.6 0.7092
At day 30 83 1.1 ± 1.8 82 1.2 ± 1.9 0.3984
Change from baseline at day 7 85 0.0 ± 1.7 85 0.0 ± 1.9 0.5236
Change from baseline at day 30 83 −1.0 ± 2.3**** 82 −0.6 ± 2.0*** 0.2207
Lissamine staining score (mean ± SD)
Baseline 90 2.9 ± 3.2 90 2.7 ± 3.1 0.6162
At day 7 85 2.9 ± 3.3 85 2.6 ± 3.2 0.7955
At day 30 83 2.1 ± 2.4 82 2.3 ± 2.6 0.4380
Change from baseline at day 7 85 −0.2 ± 2.5 85 −0.3 ± 2.8 0.7685
Change from baseline at day 30 83 −1.0 ± 2.6**** 82 −0.6 ± 2.6** 0.2404
SD, standard deviation.
*P values for the difference between groups calculated using Wilcoxon rank sum test.
**P = 0.0268; ***P = 0.0070; ****P ≤ 0.0004 for change from baseline calculated using Wilcoxon signed rank test.
Significant changes from baseline are indicated in bold font.
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Table 4 OSDI questionnaire and patient subjective symptom evaluation scores at baseline and after cataract surgery
Subject assessment
Treatment group Control group P
value*n Score n Score
OSDI questionnaire score (mean ± SD)
Baseline 90 41.8 ± 20.8 90 44.8 ± 20.9 0.2116
At day 7 85 15.6 ± 16.8 85 18.1 ± 19.5 0.4934
At day 30 83 12.7 ± 11.3 82 14.2 ± 13.8 0.7243
Change from baseline at day 7 85 −26.7 ± 20.3** 85 −27.2 ± 22.7*** 0.7447
Change from baseline at day 30 83 −29.9 ± 19.4*** 82 −30.8 ± 20.6*** 0.7748
Subjective symptom evaluation score (mean ± SD)
Baseline 90 11.8 ± 6.2 90 11.5 ± 6.0 0.7700
At day 7 85 6.1 ± 5.3 85 6.4 ± 5.2 0.4737
At day 30 83 5.1 ± 3.6 82 5.6 ± 4.0 0.5971
Change from baseline at day 7 85 −5.9 ± 5.2** 85 −5.4 ± 5.6*** 0.9018
Change from baseline at day 30 83 −7.0 ± 4.7** 82 −6.2 ± 5.8*** 0.6069
OSDI, Ocular Surface Disease Index; SD, standard deviation.
*P values for the difference between groups calculated using Wilcoxon rank sum test except for OSDI. Change from baseline at day 30 calculated using t-test.
**P < 0.0001 for change from baseline calculated using Wilcoxon signed rank test.
***P < 0.0001 for change from baseline calculated using paired t-test.
Significant changes from baseline are indicated in bold font.
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this possibility. One possible, alternative explanation for
this observation is that the ocular surface may have
recovered from damage caused by phacoemulsification.
Consistent with this possibility, the post-surgical decrease
in symptoms observed in the treatment and control
groups may be attributable to enhanced vision as a result
of phacoemulsification, although it is also possible that the
questionnaires used were not optimally designed to assess
dry eye following cataract surgery.
CMC is a polymer composed of glucopyranose subunits
with anionic charge and high microviscosity properties,
which allow retention on the cornea for a prolonged time
period. An in vitro study reported that CMC may remain
bound to human corneal epithelial cells (HCECs) for 2 h,
and that CMC may bind to HCECs through interactions
between glucopyranose subunits and glucose transporters
[22]. A single-center, double-masked, randomized, cross-
over study also demonstrated that CMC 1% ophthalmicTable 5 Adverse events reported by patients in either the
treatment group or control group





High intraocular pressure 3 (3.5) 1 (1.2)
Tearing 1 (1.2) 1 (1.2)
Eye swelling 1 (1.2) 1 (1.2)
Foreign body sensation 1 (1.2) 2 (2.4)
Photophobia 0 (0) 1 (1.2)
Red eye 0 (0) 1 (1.2)
Impaired vision 0 (0) 1 (1.2)solution prolonged TBUTand improved the Ocular Protec-
tion Index for at least 20 min after instillation [23]. Since
reductions in TBUT after cataract surgery have been
reported previously [6,7], administering artificial tears to
stabilize the tear film may thus help prevent the develop-
ment/worsening of dry eye after phacoemulsification.
It is unclear why post-surgical TBUT values observed
in this study were similar in the treatment and control
groups of patients who had dry eye prior to surgery.
However, since steroids can reduce inflammation in the
injured ocular surface epithelium of patients with dry
eye, and prednisolone was part of the post-surgical ther-
apy administered to the entire study population, it is
possible that prednisolone prevented the detection of a
difference between the treatment and control groups.
Nonetheless, at day 30 post-cataract surgery, TBUT de-
creased from baseline in the control group, but im-
proved in the treatment group. This finding is consistent
with that of a previous study, which demonstrated that
CMC prolonged TBUT in patients with mild to moder-
ate dry eye [24]. Our study also showed that in patients
with a previous diagnosis of dry eye, CMC 1% prolonged
TBUT at days 7 and 30 post-surgery (compared with the
control group). Among patients without dry eye prior to
surgery, CMC 1% maintained normal TBUT at days 7
and 30 post-surgery; in contrast, a decrease in TBUT
was observed in the control group. These results thus
support a stabilizing effect of CMC 1% ophthalmic solu-
tion on the tear film.
As increasing evidence supports the hypothesis that
ocular surface and lacrimal gland inflammation plays a
central role in the pathogenesis of dry eye [25,26], the
Yao et al. BMC Ophthalmology  (2015) 15:28 Page 9 of 10use of postsurgical prednisolone therapy in our study
could also explain why corneal and conjunctival staining
decreased in both the treatment and control groups at
30 days post-surgery. For patients without dry eye prior
to cataract surgery, fluorescein staining and lissamine
staining scores in the treatment group decreased signifi-
cantly compared with baseline. In contrast, improvement
in epithelial staining was not observed in the control
group. These results suggest that the addition of CMC
1% may help epithelial recovery following cataract sur-
gery, consistent with other studies in which CMC was
shown to promote corneal epithelial wound closure in
both in vitro and animal models [22,27].Conclusions
Although this study was limited in that neither patients
nor investigators were masked to treatment, results
indicate that adding CMC 1% ophthalmic solution to
conventional therapy after phacoemulsification can help
manage patients with prior dry eye disease. This com-
bination can also maintain tear film stability and TBUT
in patients without dry eye disease prior to phacoemulsi-
fication. Further studies are required, designed to deter-
mine mechanisms in which CMC helps stabilize the tear
film after cataract surgery.
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